Profluent Revolutionizes Protein Design with $35M Funding Boost
March 25, 2024, 9:49 am
Profluent, a cutting-edge AI-first protein design company based in Berkeley, CA, recently secured a hefty $35 million in funding. The funding round was spearheaded by Spark Capital, with support from existing investors Insight Partners and Air Street Capital, as well as a group of angel investors from OpenAI, Salesforce, Octant Bio, and Google, including the renowned Jeff Dean, Chief Scientist of Google DeepMind. The company's Board of Directors welcomed Fraser Kelton, former Head of Product at OpenAI, and Nabeel Hyatt, a general partner at Spark Capital, to steer the company towards its next phase of growth.
Profluent's mission is to harness the power of AI to create and validate innovative, functional proteins that have the potential to revolutionize healthcare and disease treatment. Led by CEO Ali Madani, Chief Business Officer Hilary Eaton, and VP and Head of Gene Editing Peter Cameron, PhD, Profluent utilizes deep generative models to design and validate novel proteins, enabling intentional design rather than relying on accidental discovery. The company's initial focus is on leveraging CRISPR systems to accelerate the development of essential genetic medicines.
Founded on the belief that AI can decode life's language and surpass traditional protein engineering limits, Profluent's innovative approach allows for rapid optimization across multiple functional attributes, paving the way for a new era of precision medicine. The funding will support the advancement of Profluent's proprietary LLMs and datasets, wet lab capabilities, and CRISPR gene editing technologies, bringing the company closer to achieving its goal of significantly improving healthcare outcomes.
With a seasoned executive team that includes industry veterans like Hilary Eaton and Peter Cameron, Profluent is well-positioned to lead the charge in bridging the gap between AI and biomedicine. By combining cutting-edge technologies like AI and CRISPR, Profluent aims to drive unprecedented innovation in the field of protein design, paving the way for the development of custom-designed enzymes and therapeutics that have the potential to transform the healthcare landscape.
As Profluent continues to push the boundaries of AI research in the life sciences, the company's co-founder and CEO, Ali Madani, remains steadfast in his commitment to creating breakthrough medicines that can revolutionize society. With the support of investors like Spark Capital and a team of industry experts, Profluent is poised to make biology programmable for the first time, ushering in a new era of precision medicine that has the potential to change the way we approach healthcare.
Profluent's mission is to harness the power of AI to create and validate innovative, functional proteins that have the potential to revolutionize healthcare and disease treatment. Led by CEO Ali Madani, Chief Business Officer Hilary Eaton, and VP and Head of Gene Editing Peter Cameron, PhD, Profluent utilizes deep generative models to design and validate novel proteins, enabling intentional design rather than relying on accidental discovery. The company's initial focus is on leveraging CRISPR systems to accelerate the development of essential genetic medicines.
Founded on the belief that AI can decode life's language and surpass traditional protein engineering limits, Profluent's innovative approach allows for rapid optimization across multiple functional attributes, paving the way for a new era of precision medicine. The funding will support the advancement of Profluent's proprietary LLMs and datasets, wet lab capabilities, and CRISPR gene editing technologies, bringing the company closer to achieving its goal of significantly improving healthcare outcomes.
With a seasoned executive team that includes industry veterans like Hilary Eaton and Peter Cameron, Profluent is well-positioned to lead the charge in bridging the gap between AI and biomedicine. By combining cutting-edge technologies like AI and CRISPR, Profluent aims to drive unprecedented innovation in the field of protein design, paving the way for the development of custom-designed enzymes and therapeutics that have the potential to transform the healthcare landscape.
As Profluent continues to push the boundaries of AI research in the life sciences, the company's co-founder and CEO, Ali Madani, remains steadfast in his commitment to creating breakthrough medicines that can revolutionize society. With the support of investors like Spark Capital and a team of industry experts, Profluent is poised to make biology programmable for the first time, ushering in a new era of precision medicine that has the potential to change the way we approach healthcare.